Major Shift in U.S. Drug Policy: Medical Marijuana Reclassified

In a landmark decision, the U.S. federal government has reclassified state-licensed medical marijuana from Schedule I to Schedule III, a move that promises to reshape the landscape of cannabis regulation. This change, signed by Acting Attorney General Todd Blanche, aims to facilitate research and improve access to medical treatment options. While it does not legalize marijuana, it significantly alters how the substance is treated under federal law, impacting businesses and researchers alike. The reclassification addresses long-standing frustrations among advocates who have argued against the previous categorization of cannabis alongside more dangerous drugs. This article delves into the implications of this pivotal change in drug policy.

By Narendra Chaudhary Apr 23, 2026, 23:49 IST

Significant Change in Drug Classification

The federal government has enacted a pivotal change in its drug policy, marking one of the most substantial adjustments in recent decades. On Thursday, Acting Attorney General Todd Blanche signed an order that reclassifies state-licensed medical marijuana from Schedule I to Schedule III, fulfilling a commitment made by the Trump administration last December.

Understanding the Change

It is important to clarify that this order does not legalize marijuana. Instead, it alters the federal government's approach to licensed medical marijuana, moving it from the most stringent drug category to a less regulated one. Blanche stated, "This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information," emphasizing that the Justice Department is acting on President Trump's promise to enhance access to medical treatment options for Americans.

Defining Schedule I Drugs

Schedule I represents the federal government's most restrictive drug classification, encompassing substances deemed to have no accepted medical use and a high potential for abuse. This category includes drugs like heroin, LSD, and ecstasy, alongside marijuana, which was classified as Schedule I until Thursday. Advocates have long criticized this classification, arguing that it is illogical to group cannabis with heroin, especially since 40 states have established functioning medical marijuana programs.

What Does Schedule III Entail?

In contrast, Schedule III includes drugs considered to have moderate to low potential for physical and psychological dependence. This category features substances like ketamine, anabolic steroids, and low-dose codeine products. Any marijuana-derived medicine that has received FDA approval is also classified as Schedule III. The reclassification of medical marijuana to this category has significant implications for patients, businesses, and researchers.

Implications of the Reclassification

The changes brought about by this reclassification are substantial. For cannabis businesses, the financial impact is notable. Previously, due to marijuana's Schedule I status, licensed cannabis companies were unable to deduct standard business expenses on their federal taxes, resulting in high effective tax rates that hindered profitability. This limitation will now be lifted.

For researchers, the new order simplifies the process of studying cannabis. It explicitly states that researchers will not face penalties for acquiring state-licensed marijuana or marijuana-derived products for their studies. The previous Schedule I classification posed significant obstacles to comprehensive medical research on cannabis.

Additionally, Blanche's order legitimizes the frameworks established by 40 states for their medical marijuana programs, creating a system for state-licensed producers and distributors to register with the Drug Enforcement Administration. However, it is crucial to note that marijuana not distributed through a state-licensed medical program will remain classified as Schedule I. This reclassification specifically pertains to licensed medical marijuana.

The Journey to This Decision

The path to this reclassification has been lengthy. The Biden administration had previously proposed a similar change and received nearly 43,000 public comments. The DEA was still reviewing these comments when Trump assumed office in January. Trump urged for a swift resolution, expressing frustration over the delays during an unrelated executive order signing about psychedelics. The order signed on Thursday is the culmination of this process.